PDCD1 and hepatocellular carcinoma: Another phase I/II dose-escalation, and expansion study is testing bozitinib, a c-MET inhibitor, combined with genolimzumab, an anti-PD-1 mAb, after first-line treatment for locally advanced or unresectable HCC not pretreated with a PD-1 inhibitor or a c-MET inhibitor (NCT03655613).